The immune and inflammatory responses are largely inhibited by glucocorticosteroids. In thymocytes, for example, glucocorticosteroids cause apoptosis, whereas they suppress the activity of phospholipase A2 and the production of eicosanoids in tissues actively engaged in inflammation. The immunosuppressive action of dexamethasone (DEX) was studied in vitro by employing a model cell system, namely the murine Th2 clone D10.G4.1 (D10) and its clonotypic anti-T cell receptor (TCR) mAb 3D3. Although the proliferative response of D10 cells to 3D3 stimulation was not affected by DEX, the costimulation provided by IL-1 was dramatically inhibited. Substitution of 3D3 by exogenous IL4 (as the IL-i costimulant) failed to prevent the inhibition of proliferation caused by DEX. Yet, when 3D3-mediated stimulation of TCR was supplemented with IL-2, D10 cells were capable of proliferating, even in the presence of DEX. Thus, TCR stimulation on D10 cells remained intact and their resulting propagation was not compromised by DEX treatment. These results provide evidence that immunosuppression caused by DEX is TCR independent and involves an early cytokine-signalling event. (J. Clin. Invest. 1992. 89:556-560.) 
Introduction
Glucocorticosteroids have multiple inhibitory effects on both the immune and inflammatory responses, but many aspects of these immunosuppressive actions are complex and poorly understood (1) (2) (3) (4) (5) . For instance, it has been reported that corticosteroids inhibit IL-2 synthesis and secretion in T helper cells, thereby preventing IL-2-dependent clonal expansion of activated cells (2, 6) . On the other hand, suppression ofboth IL-la and IL-I , synthesis has been observed to result from treatment of mononuclear cells with pharmacological concentrations of corticosteroids (7) (8) (9) .
The Th2 murine clone DlO.G4. 1 (D 0) constitutes a convenient system with which to study immunoregulatory mechanisms, including the immunosuppressive action of glucocorticosteroids. The specific antigen for D0 cells is egg white conalbumin and their primary activation occurs when: (a) T cell ing cells (APC) in a manner restricted by H-2k; (b) TCR is activated by the clonotypic monoclonal antibody 3D3; and (c) cells are treated with mitogenic lectins. Interleukin 1 potentiates the proliferative response subsequent to any of such routes ofinitial activation (10) . Secondary stimuli are provided by the mature T cell growth factors, IL-4 and IL-2. Th2 cells, like D1O cells, synthesize and secrete IL4 as their autocrine growth factor upon primary activation (1 1). Thus, the proliferative effect of IL-4 on D10 cells is regulated both by the steadystate levels of IL-4 produced and secreted, as well as by the expression of its cognate receptor (IL-4R) on the cell surface.
Cells of the Th2 type do not produce IL-2, but do respond to it when provided by a neighboring Thl cell or by an exogenous source. The response of Dl 0 cells to IL-2 is in turn regulated through its own receptor (IL-2R). Several reports by others, as well as our own observations, show that 3D3 stimulation of D1O cells causes IL-4 synthesis and brings about IL-l responsiveness. Importantly, the sensitivity ofthese cells to IL-2 is markedly augmented when they become activated by 3D3 (10, 12) .
In this report, we have employed the D1O cell system to study the immunosuppressive action of a potent synthetic glucocorticosteroid, i.e., dexamethasone (DEX). In particular, we examined the role of TCR in mediating DEX-induced immunosuppression and sought to correlate this effect with a specific cytokine signalling pathway(s). While proliferation ofD10 cells stimulated with 3D3 remained unaffected by DEX, the classical growth enhancement due to simultaneous treatment with IL-l and 3D3 was strongly inhibited. DEX also prevented the proliferative response brought about by IL-2 alone. However, when activation occurred through TCR stimulation induced by 3D3 supplemented with IL-2, D1O cells were able to divide normally, even in the presence ofDEX. Thus, immunosuppression caused by DEX occurs independently from activation ofT cell receptor in a manner which appears to involve an early cytokine-regulated signalling pathway(s).
Methods
Materials. The culture medium for the DlO.G4.1 cells was Click's (Irvine Scientific, Santa Ana, CA) supplemented with 10% FBS (HyClone obtained from MLA-144 supernates and adjusted to 100 U/ml using a standard cytotoxic T lymphocyte growth assay (12, 13 
Results
To determine whether DEX impairs primary activation through inhibition ofTCR function or a cytokine-related mechanism, the proliferative response of D10 cells to 3D3 and various combinations ofcytokines was studied upon treatment with DEX or not. As shown in Table I , TCR stimulation provided by 3D3 alone markedly increased the level of [3H]TdR uptake, both in the absence or presence of DEX (-5-and 20-fold, respectively). In addition, the synergistic proliferative response to both 3D3 and IL-2, although of moderate magnitude, was not affected by the glucocorticosteroid (Table I ). In fact, the relative extent of stimulation of [3H]TdR uptake (with respect to "basal" proliferation) induced by 3D3 or 3D3 and IL-2 in the presence of DEX, appears to be greater than that of their corresponding controls without DEX (Table I, lines 2 and 3). This effect clearly occurs at the expense of a 72% reduction in the basal level of thymidine uptake, which could be attributed to primary DEX-associated toxicity (3). However, the fact dence, which is severely affected by DEX. Potent inhibition of
[3H]TdR uptake by the steroid was observed at all concentrations of IL-1 that were tested (Fig. 1) .
The suppression of IL-I action by DEX is concentration dependent (Fig. 2) . Thus, when 3D3-stimulated DI0 cells were treated with IL-1 and increasing concentrations ofDEX, proliferation was steadily inhibited, even at 100 pM (25% inhibition). Importantly, none of the concentrations of DEX tested prevented significantly the response of DI0 cells to IL-2.
Since cytokines usually exert their physiological actions concomitantly with antigenic activation of the T cell receptor, it is difficult to distinguish separate signalling events which originate directly from each stimulating component. Nevertheless, treatment of D10 cells with IL-2 alone (in the absence of 3D3) gives rise, by itself, to a substantial proliferative response that exhibits a characteristic concentration-dependence on the cytokine (Fig. 3 A) . However, this effect (which clearly does not involve TCR activation) was completely abrogated by DEX treatment (Fig. 3 A) . In contrast, and as pointed out earlier (see Table I and Fig. 2) , stimulation of DIO cell growth can occur normally upon IL-2 addition to 3D3-stimulated cells, even in the presence of DEX (Fig. 3 B) .2 Thus, suppression of IL-2-stimulated cell growth by DEX takes place in the absence of activation of the T cell receptor, thereby implicating a perturbation of the IL-2 (but not the TCR) signalling pathway.
To determine whether the ability of DEX to prevent IL-2-induced cell proliferation is due to changes in the IL-2R, we examined the cellular level of this macromolecule upon steroidal treatment. For these experiments, we employed a monoclonal antibody (7D4) directed against the 55-kD a subunit of the IL-2R and estimated the number of D 10 cells bearing this receptor on the cell surface by cytofluorographic analysis (see 2 . Diminished proliferation of DI0 cells treated with 3D3 and IL-2 in the presence of DEX begins to be apparent above 40 U/ml of IL-2, which may be explained by depletion of nutrients or other endogenous growth factors.
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Discussion
Glucocorticoids are known to induce severe lymphopenia, markedly affecting the T cell subpopulation (15) . Inhibition of proliferation ofmononuclear cells by pharmacological doses of glucocorticoids also occurs when used both in vivo and in vitro. They also inhibit synthesis ofIL-2 in Th I cells, and the production of IL-1 a and IL-I B by adherent mononuclear cells is also blocked (2, (7) (8) (9) . Yet the precise mechanism by which immunosuppression of the helper T cell occurs has remained unclear.
In this study, we have examined the mechanism of immunosuppression caused by the potent glucocorticoid dexamethasone on murine Th2 Dl 0 cells, a model cellular system for studying immunomodulation in vitro. Our findings indicate that DEX produced an inhibition ofcytokine-assisted DI0 cell proliferation, irrespective of activation of the T cell receptor. First, cell growth induced by stimulating DIO cells with 3D3 alone was not appreciably affected by dexamethasone (Table  I) . Second, stimulation of DI0 cells by IL-I or IL-la and IL-4 (a combination used to indirectly monitor IL-1 action) in the absence of 3D3, was suppressed by DEX (Table I and Fig. 3) . Third, the proliferative response due to costimulation by 3D3
and IL-1 a, IL-I fl, or by the combination IL-la/IL-4, could be presented by the glucocorticosteroid as well (Table I) . Thus, proliferation of DIO cells in response to at least the cytokines IL-1 and IL-2 is blocked by glucocorticoids through a mechanism that does not involve inhibition of T cell receptor function. In fact, stimulation of TCR by 3D3 renders DIO cells refractory to suppression of IL-2-induced growth caused by dexamethasone (Fig. 3 B) .
Although the nature ofthis "protective" effect against inhibition ofcell growth by DEX remains elusive, it is not the result of differences in the cellular level of IL-2 receptors which were found to be unchanged by DEX treatment, whether or not 3D3 was present (Fig. 4) . In a global context, however, it may be possible that the well known inhibition of IL-2 synthesis by glucocorticosteroids in Thl cells (2) plays an important role in blunting the immune response. This effect, together with the disruption ofcytokine signalling shown to occur in Th2 cells in this report, could be key elements that bring about overall immunosuppression in the intact animal. A similar protective effect of IL-2 on DEX-induced DNA fragmentation and cell death has been reported (16) . Furthermore, reversion ofsteroid immunosuppression by IL-2 has been previously observed in mitogen-stimulated human peripheral mononuclear cells and mouse spleen cells, as well as in the effector function of mouse cytotoxic T lymphocyte generated in vivo and in vitro (4, 6, (17) (18) (19) (20) .
When D1O cells are activated through TCR stimulation, their proliferative rate becomes maximal within a few hours. They synthesize and secrete their autocrine growth factors (i.e., IL-4), and respond to other growth-inducing cytokines that may be present in the medium, such as IL-2 from Th 1 cells. Because of their clonal nontransformed nature, D10 cells need to be activated with antigen every two to three weeks to keep them viable in culture. Also, they require continuous supplementation with IL-2 to sustain their growth. In a previous study where D10 cells were treated with DEX, opposite results to our observations were found (21) . A major difference between that report and our study consists in the source and preparation of D10 cells. As /i kept frozen until needed, we consistently employed cells constantly kept in culture and that were at least 20 days post-antigenic stimulation. These "quiescent" cells more closely resemble the Th cells that become activated in vivo thereby constituting the optimal cell system for IL-l assays. However, all dead cells must be removed before the assay (the onset of growth arrest can be determined microscopically), such that surviving cells can respond to very low concentrations of IL-1 in the presence of 3D3. Although the authors ofthe report mentioned above claim that their DI0 cells were functionally intact after freezing/thawing it is conceivable that since their cells were actively growing at the time they were collected, they did not reach the state of quiescence required for these experiments. It is certainly difficult to reconcile their results with the widely recognized immunosuppressive character of DEX 
